Valuation: Allergan plc

Market Cap 63.66B 56.73B 52.52B 47.53B 89.54B 6,007B 90.61B 630B 247B 3,158B 239B 234B 10,062B P/E 2018
-8.76x
P/E 2019 -11.9x
Enterprise Value 80.96B 72.15B 66.8B 60.45B 114B 7,640B 115B 801B 314B 4,016B 304B 297B 12,797B EV / Sales 2018
4.24x
EV / Sales 2019 4.98x
Free-Float
99.9%
Yield 2018
2.15%
Yield 2019 1.55%
09-17 Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications CI
09-15 Allergan Aesthetics Introduces the FACTS Principles for Exosome-Based Skincare Technologies CI
09-01 Allergan Aesthetics Launches Skinmedica Barrier Calming Cream and Ha5 Hydra Collagen Facial Mist CI
04-07 Allergan Aesthetics Opens New Ami Training Center in Austin CI
03-31 Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting CI
03-30 Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting CI
03-19 Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions CI
03-04 Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients CI
11-12 Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence CI
25-09-25 AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai CI
25-08-19 Allergan Aesthetics Unveils Its Newest Hydration Hero CI
25-06-30 U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance CI
25-02-12 Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training CI
Manager TitleAgeSince
Director of Finance/CFO 56 2016-11-30
Director TitleAgeSince
Director/Board Member - 2020-05-07
Director/Board Member - 2020-05-07
Director/Board Member - 2020-05-07
Date Insider Type Main position Quantity % Market Cap. Importance
5/8/20 Issuer sale

Controller/Auditor

19,495 0.0059%
5/8/20 Issuer sale

Director

2,916 0.0009%
5/8/20 Issuer sale

Chief Financial Officer

67,678 0.0206%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+1.73% - - 63.66B
+2.62%+3.92%+60.10%+125.56% 1,133B
+2.15%+3.57%+35.96%+73.28% 621B
+0.09%-0.12%+23.78%+95.58% 503B
-0.66%+2.84%+39.22%+64.39% 379B
+2.18%+5.19%+74.32%+47.77% 370B
+1.61%+2.16%+22.66%+52.21% 292B
+1.97%+1.02%+2.30%+27.01% 262B
+2.05%+2.62%+50.49%+63.12% 237B
+1.80%-1.12%+28.11%+100.62% 190B
Average +1.33%+3.07%+37.44%+72.17% 405.16B
Weighted average by Cap. +1.63%+3.70%+42.45%+83.85%

Financials

2018 2019
Net sales 15.79B 14.07B 13.02B 11.79B 22.21B 1,490B 22.47B 156B 61.28B 783B 59.22B 57.99B 2,495B 16.09B 14.34B 13.27B 12.01B 22.63B 1,518B 22.9B 159B 62.45B 798B 60.35B 59.1B 2,543B
Net income -5.1B -4.54B -4.2B -3.81B -7.17B -481B -7.25B -50.41B -19.78B -253B -19.12B -18.72B -806B -5.27B -4.7B -4.35B -3.94B -7.41B -497B -7.5B -52.14B -20.46B -261B -19.77B -19.36B -833B
Net Debt 21.89B 19.51B 18.06B 16.34B 30.79B 2,066B 31.16B 217B 84.96B 1,086B 82.12B 80.41B 3,460B 17.3B 15.42B 14.28B 12.92B 24.34B 1,633B 24.63B 171B 67.16B 858B 64.91B 63.56B 2,735B
Logo Allergan plc
Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.
Employees
-